The launch of this journal is timely and important as it will set the focus on further research in orphan drugs...
Auckland, New Zealand (PRWEB) September 21, 2011
This international, peer-reviewed, open access journal will publish original research, reports, reviews and commentaries on all areas of the design and development of orphan drugs for the treatment of rare diseases through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines will be a feature of the journal.
Dr Aagaard is an Associate Professor at the Faculty of Pharmaceutical Sciences, University of Copenhagen in the section for Social Pharmacy. Dr Aagaard is the team leader for the scientific group working with different aspects of medicine use and health policy. Dr Aagaard's research is focused on the safety and policy of medicines, the use of medicine and pharmacoepidemiology, pharmacogenomics, and regulatory affairs. A special focus area is the safety of medicine in children and adolescents; several studies have been published on this topic.
She says, “Development of orphan drugs for the treatment of rare diseases has been of limited focus to the pharmaceutical industry, since the market for such drugs are often small and unprofitable. Politicians and regulators in the EU and US have recently acknowledged this problem, and favorable licensing conditions are offered to pharmaceutical companies who develop medications that can be granted with the orphan drug designation. The launch of this journal is timely and important as it will set the focus on further research in orphan drugs, their effectiveness, and safety from different perspectives.”
Publisher Tim Hill at Dove Medical Press added, “The appointment of Dr Aagaard as the Editor-in-Chief of Orphan Drugs: Research and Reviews is particularly exciting at this time, with the heightened level of interest in this field internationally. All of us at Dove Medical Press are committed to sustaining the highest levels of editorial integrity, rigorous and constructive peer-review, along with rapid publication times and the presentation of quality research findings.”
Dove Medical Press is a privately held publisher of 100+ open access peer-reviewed journals across the broad spectrum of science, technology, and especially medicine. Dove was founded in 2003 and has offices in the United Kingdom and New Zealand, with an active presence in the USA and a network of agents in Europe, the Americas, and Southeast Asia.